Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,710 shares of the company’s stock after acquiring an additional 2,685 shares during the period. Nisa Investment Advisors LLC’s holdings in Janux Therapeutics were worth $29,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of JANX. Barclays PLC increased its stake in Janux Therapeutics by 227.1% in the third quarter. Barclays PLC now owns 17,922 shares of the company’s stock valued at $181,000 after purchasing an additional 12,443 shares in the last quarter. FMR LLC grew its holdings in shares of Janux Therapeutics by 25.5% in the 3rd quarter. FMR LLC now owns 6,351,322 shares of the company’s stock valued at $64,021,000 after buying an additional 1,288,526 shares during the period. Old Well Partners LLC bought a new stake in shares of Janux Therapeutics in the 3rd quarter valued at $104,000. Corton Capital Inc. acquired a new stake in Janux Therapeutics during the 3rd quarter worth $111,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Janux Therapeutics by 27.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $11,592,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on JANX shares. Wedbush restated an “outperform” rating and issued a $53.00 price target on shares of Janux Therapeutics in a report on Monday, March 11th. Jonestrading began coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They set a “buy” rating and a $70.00 target price for the company. Bank of America lifted their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th. Cantor Fitzgerald began coverage on shares of Janux Therapeutics in a research report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, BTIG Research started coverage on shares of Janux Therapeutics in a research report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and an average price target of $61.33.

Janux Therapeutics Stock Up 0.4 %

Shares of JANX opened at $48.88 on Tuesday. The company has a 50 day moving average of $36.00 and a 200-day moving average of $18.49. The stock has a market capitalization of $2.53 billion, a P/E ratio of -36.48 and a beta of 4.18. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $58.69.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The firm had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.